COVID-19合并急性肾损伤患者的结局:系统综述与荟萃分析
该系统综述与荟萃分析纳入20个队列共13137例以住院为主的COVID-19确诊患者,旨在评估急性肾损伤(AKI)发生率及其与患者结局的关联。结果显示AKI患病率为17%,AKI与死亡风险升高相关(合并比值比15.27,95%CI 4.82-48.36),但研究间异质性较大。
要点
- COVID-19患者中AKI患病率为17%,约5%需肾脏替代治疗。
- AKI患者中77%为重症COVID-19,52%死亡。
- AKI与死亡风险升高相关,合并OR 15.27(95%CI 4.82-48.36)。
核心结论
- 肾功能障碍在COVID-19患者中常见,发生AKI的患者结局更差。
研究设计与样本
- 共纳入20个队列,覆盖13137例以住院为主的COVID-19确诊患者。
- 两位作者独立提取研究特征、结果、结局、研究水平偏倚风险和证据强度,未对期刊标题、作者或机构设盲。
主要发现
- 患者中位年龄56岁,男性占55%。
- 约43%的患者为重症COVID-19感染,约11%死亡。
- AKI患病率为17%;AKI患者中77%经历重症COVID-19感染,52%死亡。
- AKI与COVID-19患者死亡风险升高相关(合并比值比15.27;95%CI 4.82-48.36),但研究间及全球不同地区间存在相当大的异质性。
- 约5%的所有患者需要使用肾脏替代治疗(RRT)。
临床怎么用
- 临床应关注COVID-19患者肾功能,AKI发生提示预后不良风险升高。
局限性
- 研究间及不同地区间存在相当大的异质性。
- 需要进一步研究该关联的管理和潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There are limited data on the association of kidney dysfunction with prognosis in coronavirus disease 2019 (COVID-19), and the extent to which acute kidney injury (AKI) predisposes patients to severe illness and inferior outcomes is unclear. We aim to assess the incidence of AKI among patients with COVID-19 and examine their associations with patient outcomes as reported in the available literature thus far. METHODS: We systematically searched MEDLINE, EMBASE, SCOPUS, and MedRxiv databases for full-text articles available in English published from December 1, 2019 to May 24, 2020. Clinical information was extracted and examined from 20 cohorts that met inclusion criteria, covering 13,137 mostly hospitalized patients confirmed to have COVID-19. Two authors independently extracted study characteristics, results, outcomes, study-level risk of bias, and strength of evidence across studies. Neither reviewer was blind to journal titles, study authors, or institutions. RESULTS: Median age was 56 years, with 55% male patients. Approximately 43% of patients had severe COVID-19 infection, and approximately 11% died. Prevalence of AKI was 17%; 77% of patients with AKI experienced severe COVID-19 infection, and 52% died. AKI was associated with increased odds of death among COVID-19 patients (pooled odds ratio, 15.27; 95% CI 4.82-48.36), although there was considerable heterogeneity across studies and among different regions in the world. Approximately 5% of all patients required use of renal replacement therapy (RRT). CONCLUSIONS: Kidney dysfunction is common among patients with COVID-19, and patients who develop AKI have inferior outcomes. Additional research into management and potential mechanisms of this association is needed.
引用
- Robbins-Juarez SY, Qian L, King KL, et al. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney Int Rep. 2020. PMID: 32775814. doi:10.1016/j.ekir.2020.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。